AXL inhibition improves BRAF-targeted treatment in melanoma
Marta Nyakas(Oslo University Hospital), Kotryna Seip(Oslo University Hospital)
Cited by 45
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III Melanoma
|Journal of Clinical Oncology|2018|255
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2024|123